Eli Lilly has officially opened new research facilities at its R&D base in Erl Wood in Surrey. The site near Woking in the south of England is the pharma company’s biggest R&D site outside the US, and has been conducting neuroscience drug discovery since the 1960s. Erl Wood’s greatest claim to fame is that Lilly’s atypical antipsychotic Zyprexa (olanzapine) was discovered on the site. Now the company is building on its neuroscience research with a new facility to house scientists working on early drug development work. The £5.4 million building will house 130 staff across disciplines such as pharmacokinetics, clinical pharmacology and statistics.
